Remdesivir
證據等級: L5 | 預測適應症: 6 個
## 藥師評估報告
Remdesivir：從 COVID-19 到多發性內分泌腫瘤
一句話總結
Remdesivir 是一種抗病毒藥物，原本用於 COVID-19 的治療。TxGNN 模型預測它可能對**多發性內分泌腫瘤 (Multiple Endocrine Neoplasia)** 有效，但目前**無臨床試驗或文獻**直接支持這個特定適應症。
快速總覽
| 項目 | 內容 |
|---|---|
| 原適應症 | 新型冠狀病毒疾病（COVID-19） |
| 預測新適應症 | multiple endocrine neoplasia、HIV infectious disease、feline acquired immunodeficiency syndrome、simian immunodeficiency virus infection、neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter、homozygous familial hypercholesterolemia |
| TxGNN 預測分數 | 99.50% |
| 證據等級 | L5 |
| 台灣上市 | 已上市 |
| 許可證數 | 多張 |
| 建議決策 | Hold |
預測適應症詳細分析
1. multiple endocrine neoplasia L5 99.50% 主要分析
為什麼這個預測合理？
Remdesivir 是一種核苷類似物前藥，能夠抑制病毒的 RNA 依賴性 RNA 聚合酶（RdRp），從而阻止病毒複製。它最初是為了治療伊波拉病毒感染而開發，後來因 COVID-19 疫情而獲得緊急使用授權。
多發性內分泌腫瘤是一組遺傳性疾病，特徵是多個內分泌腺體發生腫瘤。這是一種腫瘤性疾病，與病毒感染無關。
目前尚不清楚 TxGNN 模型為何預測 remdesivir 對多發性內分泌腫瘤有效。可能的假設包括：
- 知識圖譜中的連結可能反映了某些共同的分子途徑
- 核苷類似物可能對快速分裂的腫瘤細胞有某種作用
然而，這些假設純屬推測，缺乏任何科學證據支持。
臨床試驗
目前無針對此特定適應症的臨床試驗登記。
2. HIV infectious disease L1 99.32%
臨床試驗（24 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT04359095 | PHASE2, PHASE3 | COMPLETED | 650 | Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colom... |
| NCT05587894 | PHASE2 | RECRUITING | 256 | OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Rand... |
| NCT04546581 | PHASE3 | COMPLETED | 593 | An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Control... |
| NCT05925140 | PHASE1 | RECRUITING | 1000 | Comparative LUSZ Therapeutic Study of Antiviral, Antiretroviral, and Immunosuppr... |
| NCT04843761 | PHASE3 | COMPLETED | 473 | A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and ... |
| NCT05780541 | PHASE3 | TERMINATED | 58 | A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and ... |
| NCT04570982 | N/A | UNKNOWN | 200 | Compassionate Use of Remdesivir and Convalescent Plasma Therapy for Treatment of... |
| NCT05780463 | PHASE3 | COMPLETED | 485 | A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and ... |
| NCT06729593 | PHASE3 | COMPLETED | 87 | A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and ... |
| NCT04292730 | PHASE3 | COMPLETED | 1113 | A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remd... |
| NCT04582266 | N/A | COMPLETED | 54 | Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant ... |
| NCT05605093 | PHASE3 | TERMINATED | 602 | Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE... |
| NCT04280705 | PHASE3 | COMPLETED | 1062 | A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and E... |
| NCT02818582 | PHASE2 | COMPLETED | 38 | PREVAIL IV: Double-Blind, Randomized, Two-Phase, Placebo-Controlled, Phase II Tr... |
| NCT04385719 | PHASE2 | COMPLETED | 24 | An Open-label, Randomized, Single Intravenous Dosing Study to Investigate the Ef... |
| NCT04669990 | N/A | UNKNOWN | 2000 | Remdesivir and Convalescent Plasma Therapy for Treatment of COVID-19 Infection i... |
| NCT04492475 | PHASE3 | COMPLETED | 969 | A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and E... |
| NCT04681430 | PHASE2 | COMPLETED | 22 | Reconvalescent Plasma / Camostat Mesylate Early in Sars-CoV-2 Q-PCR (COVID-19) P... |
| NCT04501978 | PHASE3 | COMPLETED | 2753 | A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and ... |
| NCT05780281 | PHASE3 | COMPLETED | 367 | A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and ... |
| NCT04292899 | PHASE3 | COMPLETED | 4891 | A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remd... |
| NCT05780437 | PHASE3 | COMPLETED | 1455 | A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and ... |
| NCT05780424 | PHASE3 | COMPLETED | 353 | A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and ... |
| NCT05780268 | PHASE3 | COMPLETED | 314 | A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and ... |
相關文獻（20 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 41136410 | 2025 | Article | Nature reviews. Disease primer | Acute SARS-CoV-2 infection. |
| 33264556 | 2021 | Article | The New England journal of med | Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. |
| 35229634 | 2022 | Article | mBio | The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-... |
| 36097825 | 2023 | Article | Clinical infectious diseases : | Qualitative Subgenomic RNA to Monitor the Response to Remdesivir in Hospitalized... |
| 33002954 | 2020 | Article | Current opinion in HIV and AID | Treatment of coronavirus disease 2019. |
| 34859557 | 2022 | Article | HIV medicine | Retrospective evaluation of an observational cohort by the Central and Eastern E... |
| 33864090 | 2021 | Article | The Journal of antimicrobial c | A combined assay for quantifying remdesivir and its metabolite, along with dexam... |
| 32876009 | 2020 | Article | The American journal of tropic | It Ain't Over Till It's Over: The Triple Threat of COVID-19, TB, and HIV. |
| 36165855 | 2022 | Article | ChemMedChem | Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of ... |
| 38028857 | 2023 | Article | Archives of Razi Institute | A Comparative Study of Antiretroviral (Lopinavir/Ritonavir) and Remdesivir Used ... |
| 37722451 | 2023 | Article | Journal of pharmaceutical scie | Plasma Protein Binding Determination for Unstable Ester Prodrugs: Remdesivir and... |
| 36347057 | 2022 | Article | Topics in antiviral medicine | CROI 2022: advances in antiviral therapy for HIV, COVID-19, and viral hepatitis. |
| 35817072 | 2022 | Article | The Lancet. Respiratory medici | Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a r... |
| 33469197 | 2021 | Article | Hypertension research : offici | Maternal endothelial dysfunction in HIV-associated preeclampsia comorbid with CO... |
| 32657527 | 2020 | Article | Journal of the International A | SARS-CoV-2 and HIV coinfection: clinical experience from Rhode Island, United St... |
| 35073629 | 2022 | Article | AIDS reviews | Oral antivirals for the prevention and treatment of SARS-CoV-2 infection. |
| 34633268 | 2022 | Article | Journal of chemotherapy (Flore | The use of antiviral drugs in children. |
| 36003629 | 2022 | Article | Frontiers in public health | SARS-CoV-2 pre-exposure prophylaxis: A potential COVID-19 preventive strategy fo... |
| 33847737 | 2021 | Article | American journal of epidemiolo | Safety of Tenofovir Disoproxil Fumarate for Pregnant Women Facing the Coronaviru... |
| 32587649 | 2020 | Article | Journal of clinical medicine r | Medical Management of COVID-19: Evidence and Experience. |
3. feline acquired immunodeficiency syndrome L5 99.07%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
4. simian immunodeficiency virus infection L5 99.07%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
5. neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter L5 99.03%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
6. homozygous familial hypercholesterolemia L5 99.03%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
台灣上市資訊
| 許可證號 | 品名 | 劑型 | 核准適應症 |
|---|---|---|---|
| 衛部藥輸字第XXXXXX號 | 韋如意注射用溶液劑100毫克/20毫升 | 注射劑 | 重度新型冠狀病毒感染症 |
安全性考量
安全性資訊請參考原廠仿單。
主要注意事項：
- 肝功能異常
- 腎功能損害患者需謹慎使用
- 輸注相關反應
藥物-疾病注意事項 (DDSI)
資料來源：DDInter 2.0（原文內容請參閱該網站）
肝臟疾病 🟡 Moderate
- 應謹慎使用本藥物。
腎臟疾病 🟢 Minor
- 不建議使用本藥物。
藥物-食物交互作用 (DFI)
資料來源：DDInter 2.0（原文內容請參閱該網站）
酒精 🟡 Moderate
- 影響：產生協同作用。可能增強藥效。風險包括：毒性增加。
- 建議：應完全避免。需監測療效或不良反應。
結論與下一步
決策：Hold
理由： 這個預測缺乏任何生物學合理性。Remdesivir 是一種專門針對病毒 RNA 聚合酶的抗病毒藥物，而多發性內分泌腫瘤是一種遺傳性腫瘤疾病，兩者在病理機轉上沒有明顯關聯。在沒有任何基礎研究或臨床證據的情況下，不建議將此預測推進到臨床應用。
若要推進需要：
- 探討 TxGNN 模型產生此預測的具體原因
- 進行基礎研究確認是否存在任何潛在的分子機轉
- 若有任何理論依據，需進行前臨床研究驗證
相關藥物報告
- Diosmin - 證據等級 L5
- Nebivolol - 證據等級 L5
- Cladribine - 證據等級 L5
- Alirocumab - 證據等級 L5
- Levamisole - 證據等級 L5
用 AI 幫我深入分析
想進一步了解這個藥物的老藥新用潛力嗎？點擊下方按鈕，直接開啟 AI 助手進行分析。
Claude：點擊後會複製提問並開啟新視窗，請按 Ctrl+V（Mac: Cmd+V）貼上
ChatGPT：點擊後直接開啟並自動帶入提問
引用本報告
如需引用本報告，請使用以下格式：
APA 格式：
TwTxGNN. (2026). Remdesivir老藥新用驗證報告. https://twtxgnn.yao.care/drugs/remdesivir/
BibTeX 格式：
@misc{twtxgnn_remdesivir,
title = {Remdesivir老藥新用驗證報告},
author = {TwTxGNN Team},
year = {2026},
url = {https://twtxgnn.yao.care/drugs/remdesivir/}
}
免責聲明
本報告僅供學術研究參考，不構成醫療建議。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
最後審核：2026-02-20 | 審核者：TwTxGNN Research Team
本報告僅供學術研究參考，不構成醫療建議。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
最後審核：2026-02-20 | 審核者：TwTxGNN Research Team
歡迎分享您對本報告的看法、補充資訊或提出問題。討論內容會同步到 GitHub Discussions。 需要 GitHub 帳號才能留言。